ClearPoint Neuro, Inc. (CLPT)

NCM – Real Time Price. Currency in USD

12.64

+0.33 (2.68%)

At close: May 12, 2026, 4:00 PM EDT

12.81

+0.17 (1.34%)

Pre-market: May 13, 2026, 4:15 AM EDT

29.04.2026

ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026

SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 first quarter on Wednesday, May 13th, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 first quarter results on Wednesday, May 13th, at 4:30 p.m.

29.04.2026

ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook

ClearPoint's stock has come under significant pressure in recent months following weaker 2026 revenue guidance and further regulatory uncertainty. Despite near-term headwinds, a step change in revenue remains likely as partner therapies are commercialized over the next few years. Independent of this, ClearPoint's forward revenue multiple looks increasingly reasonable given the company's strong competitive positioning and solid growth.

22.04.2026

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced the successful completion of the first clinical procedure utilizing the 510(k)-cleared Velocity Alpha MR High Speed Surgical Drill System. Utilized in a four-trajectory clinical trial procedure, the system highlights its scalability and potential to support a broader range of programs within the Company's partnered biologics portfolio.

20.04.2026

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's overall global infrastructure in support of its strategy to enable 20,000 cell and gene therapy procedures annually. SOLANA BEACH, CA / ACCESS Newswire / April 20, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced receipt of a Medical Device License (MDL) from Health Canada for its Neuro Navigation System, further expanding our Drug Delivery ecosystem and global footprint.

17.03.2026

ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript

17.03.2026

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.2 per share a year ago.

17.03.2026

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

Record Revenue and IRRAS Holdings Acquisition Highlight the Company's 'Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / March 17, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full year ended December 31, 2025.

Videos

No Data

There is no data to display

Press releases

22.04.2026

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

20.04.2026

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

17.03.2026

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

22.01.2026

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2. "By achieving CE Mark for the ClearPoint Navigation 3.0.2 software, we are able to unify our global navigation platform which we believe will enable consistent training and hospital IT support," commented Mazin Sabra, Chief Operating Officer at ClearPoint Neuro.

ClearPoint Neuro, Inc. (CLPT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ClearPoint Neuro, Inc. (CLPT)

ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026

ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

Videos

No Data

Press releases

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe

ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026

ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

Videos

No Data

Press releases

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe

Search stocks

ClearPoint Neuro, Inc. (CLPT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ClearPoint Neuro, Inc. (CLPT)

ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026

ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

Videos

No Data

Press releases

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe

ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026

ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro, Inc. (CLPT) Q4 2025 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Reports Q4 Loss, Tops Revenue Estimates

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

Videos

No Data

Press releases

ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint

ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results

ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe